{"id":"W2947559705","doi":"10.1200/jco.2019.37.15_suppl.3095","title":"A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Gemcitabine; Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Cancer; Bioavailability; Cervical cancer; Internal medicine; Pharmacology; Ovarian cancer; CHEK1; Oncology; Adverse effect; Cell cycle; Cell cycle checkpoint","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001366608,0.00222085,0.00184655,0.0005247884,0.0006536499,0.0009206188,0.0008922517,0.001420689,0.00456599],"category_scores_gemma":[0.0006107865,0.0007530471,0.001101147,0.0004222001,0.001234917,0.0008679503,0.0003926879,0.002950944,0.001271536],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001065805,"about_ca_system_score_gemma":0.002321889,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001508055,"about_ca_topic_score_gemma":0.003977667,"domain_scores_codex":[0.9996038,0.0001593247,0.00001432428,0.00008651261,0.00002819904,0.000107885],"domain_scores_gemma":[0.9994255,0.00006772396,0.00008956449,0.00004782352,0.00004118091,0.000328169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7467324,0.1308212,0.003522244,0.000559882,0.0007998362,0.0003340745,0.0002750641,0.001520629,0.05880689,0.0002470173,0.004583182,0.05179773],"study_design_scores_gemma":[0.3443735,0.6423315,0.005968192,0.00002087171,0.0002855722,0.0001635727,0.00006233971,0.0006691696,0.003608023,0.0001733775,0.002319972,0.00002407264],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989897,0.001201952,0.0005427335,0.0004627498,0.000162782,0.004440774,0.001342347,0.0001361365,0.001813463],"genre_scores_gemma":[0.9863257,0.001341623,0.001560434,0.0008954448,0.0001590393,0.003505748,0.002467768,0.0000323506,0.003711923],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00456599,"threshold_uncertainty_score":0.01527476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04307739164022831,"score_gpt":0.4383624701805542,"score_spread":0.3952850785403259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}